GLPwatch
Papers (12034)
Page 35 of 201, ranked by citation count.
- Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge.
- Effects of glucagon-like peptide-1 receptor agonists on upper endoscopy in diabetic and nondiabetic patients.
- GSK2374697, a novel albumin-binding domain antibody (AlbudAb), extends systemic exposure of exendin-4: first study in humans--PK/PD and safety.
- Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog.
- The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist.
- Exendin-4 Reverses Biochemical and Functional Alterations in the Blood-Brain and Blood-CSF Barriers in Diabetic Rats.
- Role of apolipoprotein C-III overproduction in diabetic dyslipidaemia.
- Improvement of Transdermal Delivery of Exendin-4 Using Novel Tip-Loaded Microneedle Arrays Fabricated from Hyaluronic Acid.
- Rationally Designed Dendritic Silica Nanoparticles for Oral Delivery of Exenatide.
- Expression of SIRT1 in the ovaries of rats with polycystic ovary syndrome before and after therapeutic intervention with exenatide.
- Racial and Ethnic Disparities in Financial Barriers Among Overweight and Obese Adults Eligible for Semaglutide in the United States.
- Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis.
- GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials.
- Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice.
- Brain GLP-1 and insulin sensitivity.
- Liraglutide prevents hypoadiponectinemia-induced insulin resistance and alterations of gene expression involved in glucose and lipid metabolism.
- The Antiobesity Effect and Safety of GLP-1 Receptor Agonist in Overweight/Obese Patients Without Diabetes: A Systematic Review and Meta-Analysis.
- Oral Semaglutide Induces Loss of Body Fat Mass Without Affecting Muscle Mass in Patients With Type 2 Diabetes.
- Efficacy and safety of tirzepatide, dual GLP-1/GIP receptor agonists, in the management of type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.
- Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease.
- Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial.
- Adults with early-onset type 2 diabetes (aged 18-39 years) are severely underrepresented in diabetes clinical research trials.
- The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity.
- Efficacy and safety of the dual GIP and GLP-1 receptor agonist tirzepatide for weight loss: a meta-analysis of randomized controlled trials.
- Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease.
- Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
- Efficacy and safety of once-weekly tirzepatide in Japanese patients with obesity disease (SURMOUNT-J): a multicentre, randomised, double-blind, placebo-controlled phase 3 trial.
- Glucagon-like Peptide-1 receptor agonist treatment patterns among type 2 diabetes patients in six European countries.
- The protective effects of lixisenatide against inflammatory response in human rheumatoid arthritis fibroblast-like synoviocytes.
- Liraglutide 3.0 mg for weight management: weight-loss dependent and independent effects.
- Anti-diabetic effects of GLP1 analogs are mediated by thermogenic interleukin-6 signaling in adipocytes.
- Inventing Liraglutide, a Glucagon-Like Peptide-1 Analogue, for the Treatment of Diabetes and Obesity.
- Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years.
- Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study.
- Exendin-4 improved rat cortical neuron survival under oxygen/glucose deprivation through PKA pathway.
- Novel coumarin modified GLP-1 derivatives with enhanced plasma stability and prolonged in vivo glucose-lowering ability.
- Anti-obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 international evidence-based guideline.
- Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [<sup>64</sup>Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial.
- 3-Iodothyronamine: a modulator of the hypothalamus-pancreas-thyroid axes in mice.
- Long term exendin-4 treatment reduces food intake and body weight and alters expression of brain homeostatic and reward markers.
- Factors associated with weight loss response to GLP-1 analogues for obesity treatment: a retrospective cohort analysis.
- Alterations in energy balance following exenatide administration.
- Liraglutide Improves Cognitive and Neuronal Function in 3-NP Rat Model of Huntington's Disease.
- Counter-regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo-controlled, double-blind, crossover trial.
- Ex vivo imaging of pancreatic beta cells using a radiolabeled GLP-1 receptor agonist.
- Real-world use of once-weekly semaglutide in patients with type 2 diabetes: Results from the SURE Switzerland multicentre, prospective, observational study.
- Restoration of cerebral and systemic microvascular architecture in APP/PS1 transgenic mice following treatment with Liraglutide™.
- LOX-1, a bridge between GLP-1R and mitochondrial ROS generation in human vascular smooth muscle cells.
- Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes.
- Pharmacologic Treatment of Obesity in Reproductive Aged Women.
- Glucagon-like peptide-1 receptor agonist-based agents and weight loss composition: Filling the gaps.
- Effect of the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide on alcohol consumption in alcohol-preferring male vervet monkeys.
- Liraglutide alleviates H<sub>2</sub>O<sub>2</sub>-induced retinal ganglion cells injury by inhibiting autophagy through mitochondrial pathways.
- A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Anti-Diabetic Drugs.
- Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects.
- Attenuation of carotid neointimal formation after direct delivery of a recombinant adenovirus expressing glucagon-like peptide-1 in diabetic rats.
- Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK.
- DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice.
- Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial.
- Liraglutide as Adjunct to Insulin Treatment in Patients with Type 1 Diabetes: A Systematic Review and Meta-analysis.